Multiple sclerosis (MS) is a heterogeneous disease in which diverse genetic, pathological and clinical backgrounds lead to variable therapy response. Accordingly, MS care should be tailored to address disease traits unique to each person. At the core of personalized management is the emergence of new knowledge, enabling optimized treatment and disease-modifying therapies. This overview analyzes the promise of genetic and nongenetic biomarkers in advancing decision-making algorithms to assist diagnosis or in predicting the disease course and therapy response in any given MS patient.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2217/bmm.12.113 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!